In the Claims

1-5 (canceled)

6. (new) An isolated polypeptide comprising a mutant C-C chemokine of RANTES, MIP-1α, MIP-1β and their muteins having at least 90% homology with the corresponding wild-type (WT) molecule, said mutant comprising at least one non-conservative mutation in the 40's dibasic site.

7. (new) The isolated polypeptide according to claim 6, wherein the muteins have from 95% to 99% of homology with the corresponding WT molecule.

8. (new) The isolated polypeptide according to claim 6, wherein said mutant contains Alanine or Glutammic Acid in at least one of the positions of the 40's dibasic site.

9. (new) The isolated polypeptide according to claim 6, wherein said mutant comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, and 9.

10. (new) A composition comprising a mutant C-C chemokine of RANTES, MIP-1α, MIP-1β and their muteins having at least 90% homology with the corresponding wild-type (WT) molecule, said mutant comprising at least one non-conservative mutation in the 40's dibasic site and a pharmaceutically acceptable excipient.

11. (new) An isolated polynucleotide encoding a polypeptide comprising mutant C-C chemokine of RANTES, MIP-1α, MIP-1β and their muteins having at least 90% homology with the corresponding wild-type (WT) molecule, said mutant comprising at least one non-conservative mutation in the 40's dibasic site.

12. (new) A method of administering a composition to an individual comprising:

a) preparing a composition comprising a mutant C-C chemokine of RANTES, MIP-1α, MIP-1β and their muteins having at least 90% homology with the corresponding wild-type (WT) molecule, said mutant comprising at least one non-conservative mutation in the 40's dibasic site and a pharmaceutically acceptable excipient; and

b) orally administering said composition to an individual.